



Ophthalmology

PROSPECTIVE STUDY TO COMPARE THERAPEUTIC EFFICACY OF DIFLUPREDNATE 0.05% VERSUS PREDNISOLONE ACETATE 1% IN CONTROLLING INFLAMMATION AND MACULAR OEDEMA FOLLOWING PHACOEMULSIFICATION

Dr Bahubali Jain

Associate Professor, Department of Ophthalmology, N.S.C.B Medical College, Jabalpur (MP)

Dr Saba Firdos Khan

Assistant Professor,

ABSTRACT

Background: Topical corticosteroids have been the cornerstone in the management of postoperative inflammation following cataract surgery. Due to potential side effects of the older topical steroids like prednisolone acetate and dexamethasone or betamethasone, newer potent steroids preparation like difluprednate, loteprednol or fluorometholone are now being used at lesser dose and frequency to control inflammation. There is scanty literature on the efficacy of these drugs in preventing inflammation and macular oedema in the Indian population. **Purpose:** The purpose of this study is to compare the efficacy of difluprednate 0.05% against prednisolone 1% eye drops for control of inflammation following phacoemulsification. The adverse effects of both drugs were also evaluated in this study. **Methods:** This prospective comparative study included 80 patients operated for age-related cataracts by a single surgeon at a tertiary referral eye hospital between December 2022 and November 2023. Patients received either difluprednate 0.05% emulsion (n=40 eyes) or prednisolone acetate 1% (n=40 eyes) after phacoemulsification with the same brand intraocular lens (IOL) and same phaco machine. The topical medication was initiated one day postoperatively and continued for six weeks in tapering dosage. Pain score (Visual Analogue Scale, VAS), conjunctival hyperemia, anterior chamber (AC) cell grading, corneal oedema, central retinal thickness, subclinical cystoid macular oedema (SCME), intraocular pressures (IOP) and best-corrected visual acuity (BCVA) were examined after one week and six weeks of cataract extraction. **Results:** There was no statistically significant difference observed with regards to pain score, conjunctival hyperemia, central retinal thickness ($234.44 \pm 35.75 \mu$ vs. $234.8 \pm 34.99 \mu$, p-value 0.946), SCME (16.67% vs. 13.19% , p-value 0.511), IOP (16.8 vs. 15.47 mmHg, p-value 0.101) and BCVA (BCVA 6/6 in 57.7% vs. 70.32% , p-value >0.05) between both groups. The mean change in IOP in both the groups at one week (0 ± 4.4 vs. 1.87 ± 3.54 , p-value 0.0007) and six weeks (-0.01 ± 5.53 vs. 1.88 ± 4.01 , p-value 0.004) was significant. **Conclusion:** Both the groups were equivalent with regards to their therapeutic efficacy in controlling postoperative inflammation and restoration of vision following phacoemulsification.

KEYWORDS : phacoemulsification, postoperative inflammation, difluprednate, macular edema

INTRODUCTION

The latest, safest and most popular cataract extraction technique performed worldwide is phacoemulsification with posterior chamber intraocular lens implantation [1]. It involves minimal ultrasonic power and surgical tissue manipulation, lesser postoperative inflammation and early visual restoration [1]. However, the mechanical and ultrasonic energy induces breakdown of the ocular blood-ocular barrier and thereby can potentially cause inflammation which manifests as conjunctival hyperemia, anterior chamber (AC) reaction, raised intraocular pressure (IOP) and cystoid macular oedema (CME) [2]. Topical corticosteroids remain the gold-standard drug to treat such inflammation following cataract surgery [3-7].

Difluprednate is a prednisolone derivative with structural modifications (fluorination at C6 and C9 positions and replace the 17-hydroxyl group with butyric acid). It has better anti-inflammatory activity compared to prednisolone acetate, dexamethasone and betamethasone [15,16,17]. Difluprednate exhibits better tissue penetration, bioavailability, rapid local metabolism and strong efficacy with less incidence of rising IOP [18]. It can be used in less frequent dosage (two to four times daily), leading to better compliance.

Optical coherence tomography (OCT) recording after phacoemulsification has shown a significant increase in the retinal thickness of the fovea in the postoperative period and returns to the previous levels by 28 days [19]. However, if this persists for a long time, it causes intraretinal cystic spaces, otherwise called subclinical cystoid macular oedema (SCME) [19,20]. The present study was designed to compare the efficacy and safety of difluprednate 0.05% emulsion versus 1% prednisolone acetate in controlling SCME using spectral domain OCT.

MATERIALS AND METHODS

The present prospective comparative study was conducted in the Department of ophthalmology. All patients operated for age-related cataracts with phacoemulsification under local anaesthesia by a single surgeon between December 2022 and November 2023 were included. A total of 80 eyes fulfilling the inclusion criteria (phacoemulsification with clear corneal incision and implanted foldable posterior chamber intraocular lens, completing a follow-up of six weeks) were taken into consideration. Eyes with a history of chronic ocular inflammation, glaucoma, corneal disease, previous ocular surgery, any retinal pathologies, or intra-operative compli-

cations (posterior capsular rent, nucleus drop, vitreous loss, etc.) were excluded from the study.

Patients who received difluprednate 0.05% and prednisolone 1% were categorised as group A (n=40) and group B (n=40) respectively. Baseline preoperative evaluation for best-corrected visual acuity (BCVA), IOP, central retinal thickness (CRT), dilated funduscopy, lacrimal syringing (to rule out chronic dacryocystitis), viral markers (HIV, HbsAg and HCV), blood pressure, and random blood sugar was done. Phacoemulsification (clear corneal incision) with foldable posterior chamber IOL implantation was carried out in all patients by a single experienced surgeon. The primary outcome measures were AC cells grading and CRT after one week and six weeks postoperatively. CRT was measured with the help of Spectral domain OCT [zeiss]) using a 6 mm cube scan centred on the fovea. Secondary outcome measures were ocular pain, drug tolerability, conjunctival hyperemia, corneal oedema, IOP, and BCVA at one week and six weeks postoperatively.

Difluprednate 0.05% eye drop 4 times/day $\times$ 2 weeks, 2 times/day $\times$ 2 weeks and once/day $\times$ 2 weeks. Prednisolone 1% eye drops 6 times a day, on weekly tapering doses for 6 weeks.

The primary outcome measures (AC cells grading and CRT) and secondary outcome measures (ocular pain score, drug tolerance grading, slit-lamp findings) were assessed as in Table 1.

Table 1 Assessment Of Primary And Secondary Outcome Measures.

(A) Ocular pain score (VAS) [22]	
0	No pain
1-3	Mild pain
4-6	Moderate-severe pain
7-9	Very severe pain
10	Worst pain
(B) Drug tolerance grading (eye symptoms)	
0	No discomfort
1	Mild stinging for a few seconds
2	Stinging for 30-60 seconds
3	Stinging persisted $\geq$ 60 seconds

(C) Slit-lamp findings		
Conjunctival hyperaemia (as per Japan Ocular Allergy Society grade standard photograph [23])		
0	No vasodilation	
1	Some vasodilation	
2	Extensive vasodilation	
3	Overall vasodilation	
Corneal oedema (graded from 0 to 3) [24]		
0	Clear cornea	
1	Mild oedema, evident by DM fold	
2	Moderate oedema, evident as DM fold with stromal oedema of a part of cornea	
3	Severe oedema causing difficulty in the view of the anterior chamber and iris pattern	
Aqueous cells and flare in AC according to SUN classification scheme (grades 0 to 4) [25]		
Grade	Cells/HPF	Flare
0	<1	None
0.5+	1-5	None
1+	6-15	Faint
2+	16-25	Moderate (iris/lens details clear)
3+	26-50	Marked (iris/lens hazy)
4+	>50	Intense (fibrin or plastic aqueous)

(A) Ocular pain assessment using a VAS, (B) drug tolerance grading based on our own criteria of patient discomfort and (C) evaluation of conjunctival hyperaemia, corneal oedema and anterior chamber with slit-lamp.

SUN: Standardization of Uveitis nomenclature [25], DM: Descemet's membrane, VAS: visual analogue scale, AC: anterior chamber, HPF: high power field.

The CRT was measured by Spectral domain OCT (zeiss). An increase in CRT or presence of cystic spaces on OCT without a decrease in BCVA was considered to be significant and defined as subclinical CME [19,26]. The BCVA was recorded in Snellen's chart and converted to Log MAR for analysis. The IOP was measured with the help of a noncontact tonometer (all patients had an average corneal thickness, 520-545 µm).

Statistical Analysis

Data entered were analyzed using SPSS software (version 21.0, IBM Corp., Armonk, NY). Quantitative variables were compared between the two groups using the Mann-Whitney test, and Wilcoxon signed-rank test was used for comparison between pre- and postoperative variables. Qualitative variables were compared using the Chi-square test/Fisher's exact test. The p-value of <0.05 was considered statistically significant. Yates correction was applied wherever the frequencies of sub-categories were less than 5.

RESULTS

A total of 80 patients were included (difluprednate 0.05%, n=40; prednisolone acetate 1%, n=40) in this study; of which 28(35%) patients were <60 years, 52(65%) in the age group 61-80 years. In group A, out of 40 patients, 23(57.5%) were males and 17 (42.5%) were females. In group B, there were 22 males (55 %) and 18 females (45%). The mean age of groups A and B was 63.29 ± 11.3 and 65.36 ± 8.97, respectively (t-test, p=0.173).

Primary Outcome Measures
Anterior Chamber Cells And Flare

The AC reaction at one week postoperatively in group A showed an equal number of patients having grade 0 (n=19, 47.5%) and grade 1 (n=18, 45%) aqueous cells. There were 7.5 % (n=3) of patients with grade 2 aqueous cells. In group B, the majority of patients (n=21, 52.5%) showed grade 0 while 45 % (n=18) had grade 1 and 2.5% (n=1) had grade 2 aqueous cells. The intragroup comparison showed that the difference in controlling AC reaction was not statistically significant (p=0.292, Chi-square test). At the end of six weeks, none of the patients in both groups showed any reaction.

CRT

The mean postoperative CRT measured at one week was 225.88 ± 34.84 µm and 224.57 ± 31.22 µm (t-test, p=0.79) and at six weeks were 234.44 ± 35.75 µm and 234.8 ± 34.99 µm (t-test, p=0.946) in groups A and B, respectively. There was no significant difference in CRT between the two groups indicating equivalent efficacy of topical

difluprednate and prednisolone acetate in reducing subclinical CME. Subclinical macular oedema at one week postoperatively was seen in 4/40 patients (10%) in group A as compared to 2/40 (5%) in group B (p=0.257, Chi-square test). Similarly, at the end of six weeks, macular oedema was seen in 06 patients (15%) in group A and 05 patients (12.5%) in group B (p=0.511, Chi-square test). Comparing the percentage of occurrence of macular oedema between the two groups by Chi-square test, the results were statistically not significant.

Secondary Outcome Measures
Ocular Pain Score and Drug Tolerance

Most of the patients (n=75, 93.75%) had no pain after one week except for grade 1 pain in two patients (2.5%) of group A and three patients (3.75%) of group B (p=0.249, Fisher Exact test). After six weeks, none of the patients complained of any ocular pain in both groups.

At the end of one week, there was no ocular discomfort in 95% (n=38) and 97.5% (n=39) of patients in groups A and B, respectively (p=0.066, Chi-square test). Two patients had mild stinging for <30 seconds (grade 1) and two patients had stinging for 30-60 seconds (grade 2) in group A. One patient (grade 3) in group B needed change in the drug because of severe discomfort in the eye. None of the patients experienced any form of drug discomfort at the end of six weeks.

Conjunctival Hyperemia

The majority of patients (n=26, 65%) in group A did not show conjunctival hyperemia; 13 patients (32.5%) showed grade 1 conjunctival hyperemia and only one patient showed grade 2 hyperemia. A relatively higher percentage of patients (n=30, 75 %) were congestion-free in group B after one week. However, statistically, this difference was not significant (p=0.222, Chi-square test). None of the patients showed conjunctival hyperemia at the end of six weeks.

Corneal Oedema

The corneal clarity at the end of the first week in both the groups was similar (p=0.194, Chi-square test). Only two patients in group A showed grade 2 oedema while none of the patients in group B had corneal oedema. At the end of six weeks, only one patient in group A showed persistent corneal oedema, the cause could be attributed to rising IOP in the follow-up period.

IOP

The mean IOP rise at one week and six weeks after administration of difluprednate were 0 ± 4.4 mmHg and 0.01 ± 5.53 mmHg, respectively, whereas, in group B, it was 1.87 ± 3.54 mmHg and 1.88 ± 4.01 mmHg, respectively. The change in IOP in both the groups after one week and six weeks were statistically significant (p=0.0007 and 0.004, Mann Whitney test). However, there was no significant difference in IOP between the groups in the preoperative period and postoperative periods. There were 07/ 40(17.75%) patients in the difluprednate-treated group and 4/40 (10%) patients in the prednisolone-treated group, who had IOP of > 21 mmHg (Tables 2 and 3).

Table 2 Comparison Of Intraocular Pressure (mmHg) Between Difluprednate And Prednisolone Groups.

IOP (mmHg)	Group A Diflucor (n=40)	Group B Predforte (n=40)	P-value
Preoperative			
Mean ± SD	16.79 ± 3.41	17.35 ± 2.93	0.174 (Mann Whitney test)
Range	10-26	10-25	
Postoperative one week			
Mean ± SD	16.79 ± 4.66	15.48 ± 3.63	0.063 (Mann Whitney test)
Range	9-34	8-31	
Postoperative six weeks			
Mean ± SD	16.8 ± 5.17	15.47 ± 4.43	0.101 (Mann Whitney test)
Range	8-29	8-30	

Table 3 Comparison Of Change In Intraocular Pressure (mmHg) Between Difluprednate And Prednisolone Groups.

Change in IOP (mmHg)	Group A Diflucor (n=90)	Group B Predforte (n=91)	P-value
Postoperative one week			
Mean ± SD	0 ± 4.4	1.87 ± 3.54	0.0007 (Mann Whitney test)
Range	-16 to 12	-11 to 8	
Postoperative six weeks			
Mean ± SD	-0.01 ± 5.53	1.88 ± 4.01	0.004 (Mann Whitney test)
Range	-15 to 12	-15 to 10	

BCVA

There were 26 patients (65%) with a final BCVA of 6/6 and 14 patients (35 %) with BCVA 6/9 in group A, whereas 28 patients (70%) had BCVA 6/6 and 12 patients (30%) had BCVA 6/9 in group B. There was no statistically significant difference among patients with BCVA>6/9 in both the groups at the end of the study with $X^2=0.0659$ (with Yates correction) and $P=0.797$ (p-value<0.05).

DISCUSSION

Newer techniques in phacoemulsification and the advent of safer topical steroids and non-steroidal drugs (NSAIDs) administration have led to quick visual rehabilitation after cataract surgery. Yet, postoperative inflammation in the form of AC reaction and CME continues to be the major factors causing sub-optimal visual outcomes [27]. Corticosteroids play a vital role in the treatment of this inflammation by inhibiting the release of arachidonic acid from cell membrane phospholipids and prevent the production of leukotrienes and prostaglandins. Older potent topical corticosteroids like prednisolone acetate and dexamethasone are now being replaced with newer and safer steroids like difluprednate and fluorometholone [27]. The known advantages of difluprednate related to its better patient compliance over prednisolone are its better bioavailability, enhanced penetration and dose uniformity apart from being preservative-free. Therefore, this study aimed to compare the efficacy of topical difluprednate 0.05% versus topical prednisolone acetate 1% in controlling postoperative inflammation and SCME.

In the present study, we found that the efficacy in controlling AC inflammation after cataract surgery in both difluprednate and prednisolone groups was equivalent. This is in accordance with the study by Saman et al. who showed that difluprednate is not inferior to prednisolone in reducing AC cells and flare but the resolution of signs of ocular inflammation was faster in the prednisolone group after one week of treatment [15].

Our study revealed that prednisolone could better reduce the conjunctival hyperemia in the first week of surgery, but the difference was not statistically significant. The pain score and drug discomfort were similar in both groups during the postoperative period. There was no significant difference in the reduction of corneal oedema among both groups. Similar to the study of Gurg et al., we did not observe any difference in BCVA between the groups at the end of six weeks. [3]

In the present study, the mean IOP (six weeks postop) in difluprednate treated patients was 16.8 ± 5.17 mm Hg and 15.47 ± 4.43 in the prednisolone-treated patients. There were about 18% patients with IOP of more than 21 mmHg in the difluprednate group compared to 10% of the prednisolone group. This finding was similar to Kusne et al. who reported that patients who received difluprednate showed a statistically significant increase in IOP postoperatively as compared to those on prednisolone [28].

There are certain limitations in this study. The small sample size are major limitations. The data on phacoemulsification time and power were not collected. These parameters might affect postoperative inflammation, corneal oedema and macula thickness.

CONCLUSIONS

Both the drugs are equivalent in their efficacy in reducing postoperative inflammation following phacoemulsification. The difluprednate group may cause a higher rise in IOP, and therefore should be used judiciously in patients with previous ocular hypertension and steroid responders. Difluprednate has been successfully added to the group of anti-inflammatory drugs in postcataract surgery for the past few years and remains to be so. The added advantages of being BAK-free and less frequent dosing make it more compliant and tolerable in patient.

REFERENCES

1. Torsional and burst mode phacoemulsification for patients with hard nuclear cataract: a randomized control study. Yang WJ, Wang XH, Zhao F, Mei ZM, Li S, Xiang Y. *Medicine (Baltimore)* 2019;98:0. [PMC free article] [PubMed] [Google Scholar]
2. Comparison of efficacy of difluprednate 0.05% and loteprednol gel 0.5% after cataract surgery. Aebissi B, Brooksby L, Schultze RL. *Eye Contact Lens*. 2018;44:0-42. [PubMed] [Google Scholar]
3. Increased frequency of topical steroids provides benefit in patients with recalcitrant postsurgical macular edema. Campochiaro PA, Han YS, Mir TA, et al. *Am J Ophthalmol*. 2017;178:163–175. [PubMed] [Google Scholar]
4. Management of postoperative inflammation after cataract and complex ocular surgeries: a systematic review and Delphi survey. Aptel F, Colin C, Kaderli S, Deloche C, Bron AM, Stewart MW, Chiquet C. *Br J Ophthalmol*. 2017;101:1–10. [PubMed] [Google Scholar]

5. Perioperative antibiotics and anti-inflammatory agents in cataract surgery. DeCros FC, Afshari NA. *Curr Opin Ophthalmol*. 2008;19:22–26. [PubMed] [Google Scholar]
6. Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema. Sreekantam S, Denniston AK, Murray PI. *Ocul Immunol Inflamm*. 2011;19:353–357. [PubMed] [Google Scholar]
7. Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions. Grob SR, Gonzalez-Gonzalez LA, Daly MK. *Clin Ophthalmol*. 2014;8:1281–1289. [PMC free article] [PubMed] [Google Scholar]
8. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Pleyer U, Ursell PG, Rama P. *Ophthalmol Ther*. 2013;2:55–72. [PMC free article] [PubMed] [Google Scholar]
9. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. *Invest Ophthalmol Vis Sci*. 2014;55:2993–3002. [PMC free article] [PubMed] [Google Scholar]
10. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: pooled efficacy analysis of two phase 3 studies. Sheppard JD, Foster CS, Toyos MM, Markwardt K, Da Vanzo R, Flynn TE, Kempen JH. *Ocul Immunol Inflamm*. 2019;27:484–496. [PubMed] [Google Scholar]
11. Difluprednate medical review clinical trial 002A & 002B. [Apr;2019];CDER CDER. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022212s000_MedR.pdf 2008
12. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS. *J Cataract Refract Surg*. 2009;35:26–34. [PubMed] [Google Scholar]
13. To study the efficacy of difluprednate ophthalmic emulsion and prednisolone acetate ophthalmic suspension on post-operative inflammation in cataract surgery. Garg P, Tuteja N, Qayum S. *J Clin Diagn Res*. 2016;10:0-8. [PMC free article] [PubMed] [Google Scholar]
14. Bioavailability of generic 0.05% difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial difluprednate. Mercado-Sesma A, Contreras-Rubio A, Baiza-Durán L, Olvera-Montaño O, Miranda-Robles M, Bonilla-García J. *J Ophthalmic Inflamm Infect*. 2017;7:10. [PMC free article] [PubMed] [Google Scholar]
15. Comparison of difluprednate 0.05% versus prednisolone acetate 1% eye drops following uneventful cataract surgery. Saman IS, Mostafa EM, Kamel AG, Mohammed OA. *J Clin Ophthalmol*. 2018;2:101–104. [Google Scholar]
16. Sirion Therapeutics announces FDA approval of Durezol for treatment of postoperative ocular inflammation and pain. [Apr;2019];<https://www.biospace.com/article/releases/sirion-therapeutics-announces-fda-approval-of-durezol-tm-for-treatment-of-postoperative-ocular-inflammation-and-pain/> 2008
17. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Wilson ME, O'Halloran H, VanderVeen D, et al. *Eye (Lond)* 2016;30:1187–1194. [PMC free article] [PubMed] [Google Scholar]
18. Difluprednate for inflammatory eye disorders. Mulki L, Foster CS. *Drugs Today (Barc)* 2011;47:327–333. [PubMed] [Google Scholar]
19. Foveal thickness after phacoemulsification as measured by optical coherence tomography. Georgopoulos GT, Papaconstantinou D, Niskopoulou M, Moschos M, Georgalas I, Koutsandrea C. *Clin Ophthalmol*. 2008;2:817–820. [PMC free article] [PubMed] [Google Scholar]
20. Spectral domain optical coherence tomography documented rapid resolution of pseudophakic cystoid macular edema with topical difluprednate. Chalam K, Khetpal V, Patel CJ. *Clin Ophthalmol*. 2012;6:155–158. [PMC free article] [PubMed] [Google Scholar]
21. Difluprednate 0.05% versus prednisolone acetate post-phacoemulsification for inflammation and pain: an efficacy and safety clinical trial. Palacio-Pastrana C, Chávez-Mondragón E, Soto-Gómez A, et al. *Clin Ophthalmol*. 2020;14:1581–1589. [PMC free article] [PubMed] [Google Scholar]
22. Topical versus peribulbar anesthesia in clear corneal cataract surgery. Zehetmayer M, Radax U, Skorpik C, Menapace R, Schemper M, Weghaupt H, Scholz U. *J Cataract Refract Surg*. 1996;22:480–484. [PubMed] [Google Scholar]
23. Severity classification of conjunctival hyperaemia by deep neural network ensembles. Masumoto H, Tabuchi H, Yoneda T, Nakakura S, Ohsugi H, Sumi T, Fukushima A. *J Ophthalmol*. 2019;2019:7820971. [PMC free article] [PubMed] [Google Scholar]
24. Alkali burns of the eye: pathophysiology and treatment. Pfister RR, Koski J. *South Med J*. 1982;75:417–422. [PubMed] [Google Scholar]
25. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Jabs DA, Nussenblatt RB, Rosenbaum JT. *Am J Ophthalmol*. 2005;140:509–516. [PMC free article] [PubMed] [Google Scholar]
26. Retinal thickness changes after phacoemulsification. Pardianto G, Moeloe N, Reveny J, Wage S, Satari I, Sembiring R, Srisamran N. *Clin Ophthalmol*. 2013;7:2207–2214. [PMC free article] [PubMed] [Google Scholar]
27. Difluprednate versus prednisolone acetate after cataract surgery: a systematic review and meta-analysis. KhalafAllah MT, Basiony A, Salama A. *BMJ Open*. 2019;9:0. [PMC free article] [PubMed] [Google Scholar]
28. A retrospective analysis of intraocular pressure changes after cataract surgery with the use of prednisolone acetate 1% versus difluprednate 0.05% Kusne Y, Kang P, Fintelmann RE. *Clin Ophthalmol*. 2016;10:2329–2336. [PMC free article] [PubMed] [Google Scholar]